HU0002922A3 - Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors - Google Patents

Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors

Info

Publication number
HU0002922A3
HU0002922A3 HU0002922A HU0002922A HU0002922A3 HU 0002922 A3 HU0002922 A3 HU 0002922A3 HU 0002922 A HU0002922 A HU 0002922A HU 0002922 A HU0002922 A HU 0002922A HU 0002922 A3 HU0002922 A3 HU 0002922A3
Authority
HU
Hungary
Prior art keywords
adenovirus
tumors
treatment
intratumoral delivery
angiogenesis antagonist
Prior art date
Application number
HU0002922A
Other versions
HU0002922A2 (en
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US4498097P priority Critical
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of HU0002922A2 publication Critical patent/HU0002922A2/en
Publication of HU0002922A3 publication Critical patent/HU0002922A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/484Plasmin (3.4.21.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
HU0002922A 1997-04-28 1998-04-27 Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors HU0002922A3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US4498097P true 1997-04-28 1997-04-28

Publications (2)

Publication Number Publication Date
HU0002922A2 HU0002922A2 (en) 2000-12-28
HU0002922A3 true HU0002922A3 (en) 2003-03-28

Family

ID=21935358

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002922A HU0002922A3 (en) 1997-04-28 1998-04-27 Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors

Country Status (14)

Country Link
US (2) US6638502B1 (en)
EP (1) EP0979290A2 (en)
JP (1) JP2001523103A (en)
KR (1) KR20010020342A (en)
CN (1) CN1177934C (en)
AU (1) AU753781B2 (en)
BR (1) BR9808697A (en)
CA (1) CA2288306A1 (en)
HU (1) HU0002922A3 (en)
IL (1) IL132323D0 (en)
NO (1) NO995242L (en)
PL (1) PL336523A1 (en)
WO (1) WO1998049321A2 (en)
ZA (1) ZA9803553B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
EP1746421B1 (en) * 1999-04-13 2008-07-30 Wilex AG Diagnostic and therapeutic application of antibodies against the urokinase receptor
AT340260T (en) * 1999-05-07 2006-10-15 Us Gov Health & Human Serv Method for the treatment of tumors by antiangiogenic substances
FR2794771B1 (en) * 1999-06-11 2001-08-10 Aventis Pharma Sa recombinant adenovirus encoding the specific iodine transporter (NIS)
US20020115202A1 (en) * 1999-08-13 2002-08-22 Paul Hallenbeck Adenoviral vectors including dna sequences encoding angiogenic inhibitors
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
CN1183250C (en) * 2000-12-01 2005-01-05 卫健生物科技有限公司 Virus with specigic reproduction in tumor well and effective expression of tumor angiogenesis nihibitory factor and its construction method
JP4034530B2 (en) * 2001-02-20 2008-01-16 日本ケミカルリサーチ株式会社 Anti-HIV agent
JP4689144B2 (en) 2001-02-22 2011-05-25 ノバルティス アーゲー Methods for treating ocular neovascularization
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE602004031381D1 (en) * 2003-12-26 2011-03-24 Nagoya Ind Science Res Inst Nagoya Arznei for the prevention and treatment of diseases of the disease with cd9 gen
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1712241A1 (en) * 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique Composition for treating cancer adapted for intra-tumoral administration and uses thereof
EP1739092A1 (en) 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et da la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
AT540689T (en) 2005-11-14 2012-01-15 Centre Nat Rech Scient Macroh2a non-histone domain as an inhibitor of parp-1 activity and use thereof
KR101331751B1 (en) 2006-03-24 2013-11-20 니혼 유니버서티 Method for preparation of hepatocyte using es cell
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
CN1958075A (en) * 2006-11-27 2007-05-09 林李家宓 Compsn of anti-blood generating factor contg adeno-associated virus mediation and its application
JP5351884B2 (en) 2007-04-23 2013-11-27 インターシア セラピューティクス,インコーポレイティド Suspension preparation and use of insulin secretagogue peptide
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
NZ624569A (en) 2009-09-28 2016-01-29 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513994A (en) * 1894-02-06 Seaming-machine for sheet-metal ware
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
FR2573436B1 (en) 1984-11-20 1989-02-17 Pasteur Institut Recombinant DNA comprising a nucleotide sequence coding for a specific polypeptide under the control of a promoter of adenovirus vectors containing this recombinant DNA, transformed eukaryotic cells with this recombinant DNA products of excretion of these transformed cells and their applications, especially in vaccine constitution
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
FR2601676B1 (en) 1986-07-17 1988-09-23 Rhone Poulenc Sante Process for the preparation of taxol and 10-desacetyl taxol
FR2601675B1 (en) 1986-07-17 1988-09-23 Rhone Poulenc Sante Taxol derivatives, their preparation and pharmaceutical compositions containing them
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
WO1989007150A1 (en) 1988-02-05 1989-08-10 The Trustees Of Columbia University In The City Of Retroviral packaging cell lines and processes of using same
FR2629818B1 (en) 1988-04-06 1990-11-16 Centre Nat Rech Scient taxol Preparation Method
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
FR2662440B1 (en) 1990-05-22 1992-07-31 Rhone Poulenc Sante Stereoselective process for the preparation of derivatives of phenylisoserine.
FR2662441B1 (en) 1990-05-22 1992-10-23 Rhone Poulenc Sante Process for the enantioselective preparation of phenylisoserine derivatives of.
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
WO1992005263A1 (en) 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
FR2678833B1 (en) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa New pharmaceutical compositions based on derivatives of taxane.
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa New biologically active polypeptides, their preparation and pharmaceutical compositions containing them.
MX9305855A (en) * 1992-09-24 1995-01-31 Tadatsugu Taniguchi Factors 1 and 2 regulators Interferon in diagnosing latumorigenicidad.
FR2698543B1 (en) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa New compositions based on taxoids.
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
FR2698871B1 (en) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa New taxoids, their preparation and pharmaceutical compositions containing them.
WO1994021807A2 (en) 1993-03-19 1994-09-29 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. hsv) as vaccine
FR2705361B1 (en) 1993-05-18 1995-08-04 Centre Nat Rech Scient Viral vectors and use in gene therapy.
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenovirus and corresponding complementation lines.
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
CZ287157B6 (en) 1993-07-13 2000-10-11 Rhone Poulenc Rorer Sa Defective recombinant adenovirus and pharmaceutical preparation in which said adenovirus is comprised
AU7477394A (en) 1993-07-30 1995-03-27 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
FR2714830B1 (en) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa A composition containing nucleic acids, preparation and uses.
FR2715847B1 (en) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa A composition containing nucleic acids, preparation and uses.
CA2187818A1 (en) 1994-04-15 1995-10-26 Robert W. Overell Gene delivery fusion proteins
MX9605109A (en) 1994-04-26 1997-08-30 Childrens Medical Center Angiostatin and method of use for inhibition of angiogenesis.
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
FR2722191B1 (en) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Process for the preparation of the trihydrate of the (2R, 3S) -3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate-4-benzoyloxy-5beta acetoxy2alpha, 20epoxy-1,7beta, 10beta trihydroxy-9-oxo-tax-11-en -13alpha-yl
FR2726285B1 (en) 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus devoid of viable contaminating particles, preparation and use
FR2727679B1 (en) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa New transfection agents and their pharmaceutical applications
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (en) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa A pharmaceutical composition containing nucleic acids, and uses thereof
FR2736915B1 (en) 1995-07-19 1997-08-22 Rhone Poulenc Rorer Sa Variants of the p53 protein and therapeutic uses
WO1997015666A1 (en) 1995-10-23 1997-05-01 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
CA2264012C (en) * 1996-08-13 2011-04-26 Chiron Corporation Compositions and methods for polynucleotide delivery

Also Published As

Publication number Publication date
BR9808697A (en) 2000-07-11
WO1998049321A3 (en) 1999-02-25
JP2001523103A (en) 2001-11-20
WO1998049321A8 (en) 1999-04-08
WO1998049321A2 (en) 1998-11-05
CA2288306A1 (en) 1998-11-05
CN1177934C (en) 2004-12-01
HU0002922A2 (en) 2000-12-28
ZA9803553B (en) 1999-02-04
AU753781B2 (en) 2002-10-31
KR20010020342A (en) 2001-03-15
IL132323D0 (en) 2001-03-19
US20040265273A1 (en) 2004-12-30
AU7909698A (en) 1998-11-24
CN1254378A (en) 2000-05-24
EP0979290A2 (en) 2000-02-16
NO995242L (en) 1999-12-27
PL336523A1 (en) 2000-07-03
NO995242D0 (en) 1999-10-27
US6638502B1 (en) 2003-10-28

Similar Documents

Publication Publication Date Title
DE69534080D1 (en) Controlled, local administration of chemotherapeutic agents for the treatment of solid tumors
DE69831421D1 (en) Compositions for nasal administration
AU767725C (en) Modified peptides as therapeutic agents
DK1129741T3 (en) Inhaler atomizer
DE69940354D1 (en) Adenovirus formulations for gene therapy
DE69735643D1 (en) Il12 for gene therapy of tumors
DE69841982D1 (en) Compositions for use in gene therapy for the treatment of hemophilia
EG24678A (en) Combination therapy
DK0883404T3 (en) Combination therapy for osteoporosis
GB9928265D0 (en) Inhaler
ZA9710182B (en) Use of GLP-1 peptides.
EP1229962A4 (en) Laser system for improved transbarrier therapeutic radiation delivery
IL130786D0 (en) Transdermal therapeutic system
AU6256798A (en) Radiation delivery balloon
GB9926632D0 (en) Dressing
EP1007637A4 (en) Methods for increasing the efficiency of recombinant aav product
ZA9800078B (en) New formulation for inhalation
GB9905010D0 (en) Therapeutic agents
AT332386T (en) Defektive recombinant adenovires for tumor gene therapy
GB0013674D0 (en) Therapeutic use
IL150484D0 (en) Novel colloid synthetic vectors for gene therapy
HU0002183A3 (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
SG80049A1 (en) Delivery system
IL145620D0 (en) A polypeptide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
IL149421A (en) Pharmaceutical compositions containing fed mode inducing agents

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees